Stay updated on Cabozantinib in HR+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib in HR+ Breast Cancer Clinical Trial page.

Latest updates to the Cabozantinib in HR+ Breast Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check16 days agoChange DetectedRevision: v3.4.2 replaces v3.4.1 on the page, reflecting an internal update. No user-facing content or functionality appears to be affected.SummaryDifference0.1%

- Check23 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1; no changes to study data or core page content.SummaryDifference0.1%

- Check31 days agoChange DetectedGlossary is now shown by default (Show glossary). The labels related to QC criteria and FEAR Act data have standardized capitalization (Last Update Submitted that Met QC Criteria; No FEAR Act Data) and the revision tag updated from v3.3.4 to v3.4.0.SummaryDifference0.2%

- Check45 days agoChange DetectedRevision: v3.3.4 was added and v3.3.3 was removed, indicating a minor maintenance update to the site. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check66 days agoChange DetectedDifference0.3%

- Check89 days agoChange DetectedThe page now displays a revision note indicating the site version was updated from v3.3.1 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Cabozantinib in HR+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib in HR+ Breast Cancer Clinical Trial page.